The U.S. Food and Drug Administration has approved LISRAYA, or brepocitinib, 30 mg tablets for adults with dermatomyositis, giving patients the first FDA-approved oral treatment specifically indicated for a disease that can combine debilitating muscle weakness with painful and persistent skin manifestations. Priovant Therapeutics, a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), said the once-daily therapy became available for prescribing in the United States immediately following the August 27, 2026 approval.
The approval represents more than another product entering the autoimmune market. Dermatomyositis has historically been managed with corticosteroids, conventional immunomodulatory therapies and intravenous immunoglobulin, often requiring physicians to balance incomplete disease control against the consequences of prolonged immunosuppression and steroid exposure. LISRAYA introduces a targeted oral approach based on simultaneous inhibition of tyrosine kinase 2, or TYK2, and Janus kinase 1, or JAK1, signaling pathways implicated in the inflammatory biology of dermatomyositis.
Why does the FDA approval of LISRAYA matter for dermatomyositis treatment?
Dermatomyositis is a systemic autoimmune inflammatory disease rather than simply a muscle or skin disorder. Patients can experience progressive muscle weakness, extensive rashes, itching, pain, impaired physical function and loss of independence, while treatment may require prolonged courses of glucocorticoids and other immunomodulating medicines. The FDA said the approval addresses a substantial unmet need because patients have had limited approved options and frequently relied on therapies developed for other diseases.
LISRAYA therefore changes the treatment landscape in two important ways. It provides an oral therapy with a mechanism designed around inflammatory signaling involved in the disease, while its pivotal clinical program also demonstrated that improving dermatomyositis activity could occur alongside a reduction in systemic corticosteroid exposure. That second point may become particularly important in clinical practice because steroid-sparing efficacy is not merely a convenient secondary outcome for patients who may otherwise require long-duration glucocorticoid treatment.
Priovant described LISRAYA as the first and only targeted therapy approved for dermatomyositis, while the FDA more conservatively emphasized that it is the first approved oral treatment for adults with the disease. The distinction matters because intravenous immunoglobulin has previously demonstrated efficacy and has an FDA-approved role in adult dermatomyositis, but LISRAYA introduces a fundamentally different oral therapeutic approach.
What did the Phase 3 VALOR trial show about brepocitinib efficacy?
The FDA decision is supported by the Phase 3 VALOR study, a 52-week, double-blind, randomized and placebo-controlled trial involving 241 adults with dermatomyositis. Participants were assigned to brepocitinib 30 mg, brepocitinib 15 mg or placebo, with 81 patients receiving each brepocitinib dose and 79 receiving placebo. Patients could continue certain standard therapies, while systemic glucocorticoids were tapered during the study.
The pivotal result came from the 30 mg dose that ultimately became the approved LISRAYA regimen. At week 52, patients receiving brepocitinib 30 mg achieved a mean Total Improvement Score of 46.5 compared with 31.2 for placebo, producing a difference of 15.3 points and a statistically significant result. The 15 mg dose produced a mean score of 37.5 and did not demonstrate the same statistically significant superiority over placebo, reinforcing the rationale for advancing the 30 mg regimen.
The treatment effect was also not confined to a single composite endpoint. The 30 mg dose outperformed placebo across all nine key secondary endpoints assessed in the multiplicity-controlled analysis, including measures of skin disease, functional disability and systemic glucocorticoid tapering. Improvements were observed as early as week four and continued through the 52-week study period.
That combination of muscle, skin and functional outcomes gives the approval greater clinical significance than a narrowly positive trial result would suggest. Dermatomyositis can manifest differently across patients, meaning a drug capable of producing benefits across several disease domains may have greater practical relevance than one whose effects are concentrated on only one component of the disease.
How much did LISRAYA reduce patients’ dependence on corticosteroids?
The steroid-sparing findings may become one of LISRAYA’s strongest differentiating features as physicians begin using the therapy outside clinical trials. By the end of VALOR, 55% of patients treated with LISRAYA had achieved both moderate-or-better improvement on the Total Improvement Score and minimal or no steroid use, compared with 30% of patients receiving placebo.
Among participants taking at least 7.5 mg per day of prednisone-equivalent oral corticosteroids when the trial began, 62% of LISRAYA-treated patients reduced their dose to 2.5 mg per day or less by week 52, compared with 38% on placebo. Some 45% of patients receiving LISRAYA discontinued corticosteroids completely, compared with 29% of the placebo group.
Those numbers are commercially and clinically relevant because the value proposition for a new immune therapy is not based solely on controlling disease activity. If physicians can maintain or improve control while meaningfully reducing chronic corticosteroid exposure, LISRAYA could address a treatment burden that accompanies the underlying disease itself. The real-world durability of that steroid-sparing benefit, however, will become clearer only after broader use across patients with different comorbidities and prior treatment histories.
What do the latest skin-specific results add to the LISRAYA approval story?
A separate analysis of VALOR published in JAMA Dermatology immediately before the FDA decision provides additional evidence around one of the most visible and difficult aspects of dermatomyositis. The analysis found improvements across measurements of cutaneous disease activity, itching and skin-related quality of life among patients receiving brepocitinib 30 mg.
Among patients who had at least moderate itching when they entered the trial, 54% of those receiving brepocitinib achieved a clinically meaningful improvement by week four compared with 10% receiving placebo. By week 52, those proportions had increased to 74% and 33%, respectively.
The remission-oriented skin outcomes were similarly notable. Among patients beginning the study with moderate-to-severe skin disease, 46% of those treated with brepocitinib reached a rating of clear or almost clear skin at week 52, compared with 22% receiving placebo. Functional skin remission based on the Cutaneous Dermatomyositis Activity and Severity Index was achieved by 44% of the brepocitinib group compared with 21% of placebo recipients.
These results add another dimension to the approval because skin manifestations can remain highly burdensome even when muscle symptoms are manageable. A therapy capable of improving both components gives dermatologists and rheumatologists a potential reason to view LISRAYA as more than a muscle-focused treatment.
What safety considerations could influence adoption of LISRAYA?
The efficacy results are accompanied by an important safety framework. LISRAYA carries a boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis, reflecting safety concerns associated with the JAK inhibitor class. The prescribing information also advises against combining LISRAYA with other JAK inhibitors, TYK2 inhibitors or biologic disease-modifying antirheumatic drugs.
In VALOR, serious infections occurred in 10% of patients receiving brepocitinib 30 mg compared with 1% receiving placebo, although no deaths occurred during the trial. Frequently reported adverse reactions included upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, joint pain, diarrhea, back pain, influenza and acne.
The eventual positioning of LISRAYA will therefore depend partly on how clinicians weigh its multi-domain efficacy and steroid-sparing potential against those warnings, particularly when treating patients with infection, cardiovascular or thrombotic risk factors. The approval gives physicians a new option, but it does not remove the need for patient selection, monitoring and individualized risk-benefit decisions.
Could dermatomyositis become only the first commercial market for brepocitinib?
The strategic importance of the approval extends beyond dermatomyositis because Priovant is attempting to develop brepocitinib as a broader autoimmune franchise. Roivant has Phase 3 programs underway in non-infectious uveitis and cutaneous sarcoidosis, while a Phase 2b/3 program is evaluating the drug in lichen planopilaris. Roivant expects Phase 3 non-infectious uveitis data in the second half of 2026, making that readout the next major test of whether the TYK2/JAK1 mechanism can translate into a multi-indication commercial platform.
The drug originated at Pfizer Inc., which licensed development rights and U.S. and Japan commercial rights to Priovant in 2021. Roivant reported that, as of March 31, 2026, it owned 72% of Priovant’s outstanding shares, or 66% on a fully diluted basis. Under the licensing arrangement, Priovant owes Pfizer tiered royalties in the sub-teens on net sales in its territory and could owe a mid-tens-of-millions sales milestone if annual sales exceed a specified threshold in the mid-hundreds of millions of dollars.
That structure means the economics are more complicated than those of a wholly internally developed product, but the approval nevertheless turns brepocitinib from a late-stage development asset into a commercial medicine. Roivant had previously expected a U.S. launch by the end of September 2026, making the announcement that LISRAYA is immediately available a faster commercial transition than its earlier guidance implied.
Investor sentiment reflected the significance of the regulatory milestone without producing an extreme one-day reaction. Roivant Sciences shares closed August 27 at $37.58, up about 2.3% for the session. The stock was up roughly 73% from the start of 2026, suggesting investors had already assigned substantial value to the company’s clinical pipeline and upcoming catalysts before the LISRAYA decision arrived.
What should the pharmaceutical industry watch after the LISRAYA launch?
LISRAYA enters the market with an unusually straightforward clinical message for a rare autoimmune therapy: a once-daily oral medicine delivered statistically significant improvement across multiple disease domains while enabling a meaningful proportion of patients to sharply reduce or discontinue corticosteroids. Those attributes could support adoption, particularly among patients whose dermatomyositis remains inadequately controlled on conventional immunosuppressive approaches.
The unresolved question is how efficiently Priovant can convert that clinical differentiation into real-world access. Rare-disease identification, coordination between dermatology and rheumatology specialists, specialty-pharmacy distribution, payer requirements and the boxed JAK-class safety warnings could all influence the speed of uptake. Priovant has established its LISRAYA My Compass Support program to assist eligible patients with insurance and financial-access processes, but commercial execution will now become as important as clinical data.
From a broader drug-development perspective, the approval also gives Roivant a clinical validation point for brepocitinib’s dual TYK2/JAK1 strategy. Dermatomyositis alone represents a meaningful specialty opportunity, but the long-term value of the asset could rise considerably if forthcoming studies demonstrate that the same mechanism works across non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris. The FDA decision therefore closes one regulatory chapter while opening a much larger question about whether LISRAYA becomes a single rare-disease product or the first commercial entry in a broader autoimmune franchise.
